BayCom (BCML) Stock Price Faces Q3 Earnings Reality Check

BayCom came into this Q3 2026 earnings release priced for perfection, with the stock trading on a trailing P/E of 35.8x and expectations running hot. The first print after the numbers told a different story. Shares fell 4.5% on the day to about US$30.47 as investors reacted to a quarter that showed basic EPS of roughly US$0.10 on revenue of US$18.9 million and a trailing net margin of 10%.

The gap between that high valuation and more modest recent profitability is now front and center for anyone holding or tracking the stock.

Love BayCom’s premium P/E but uneasy about that 10% net margin and soft quarterly EPS? You can compare it with peers that have stronger profitability profiles using our list of solid balance sheet and fundamentals stocks (25 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$18.91 million vs. US$22.68 million (declined 16.6%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$1.15 million vs. US$5.01 million (declined 77.2%)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.10 vs. US$0.46 (declined 77.1%)
• Net Interest Margin (NIM, Trailing 12 Months to Q3 2026 vs. Trailing 12 Months to Q3 2025): 10.0% net profit margin vs. 24.4% net profit margin (compressed 14.4 percentage points)

BayCom’s earnings forecast jumps even as margins have slipped. Ask Charlie what makes BayCom’s 82% earnings growth forecast believable.

BayCom bullish story meets weaker earnings pulse

For anyone leaning into the BayCom business banking story, these results ask for patience. The model still leans on diversified lending and fee potential, yet the income statement shows pressure. Revenue declined 16.6% year on year and basic EPS fell from US$0.46 to US$0.10. That combination points to a franchise that is intact on paper but currently earning less per relationship. The modest 30 day share gain before the report suggests some optimism was building, which now looks ahead of the near term profit trend.

Profit squeeze reinforces BayCom risk watchlist

The bear case around BayCom focuses on earnings sensitivity and balance sheet risk. Recent numbers give that view more weight. Net income excluding extra items declined 77.2% year on year and the trailing net margin moved from 24.4% to 10%. That is a sharp squeeze in banking terms. Revenue contraction of 16.6% alongside such a margin step down points to both top line and profitability pressure, not just one off noise. With the share price down 4.5% on the day and 7 day returns also weaker, investors are treating these risks as immediate, not theoretical.

Access where the surface looks calm but the models start to disagree on BayCom’s next few years by reviewing the street’s full multi year revenue, EPS and valuation curve in the analyst estimates for BayCom

Hunt For Quieter Mispricing

BayCom recently highlighted how a confident narrative can contrast with softer earnings, narrowing enthusiasm. The real opportunity could sit in stocks that appear undervalued before consensus assessments adjust.

• Company 1 - 25% below our estimate - sells injectable treatments for weight loss and diabetes that are reshaping metabolic disease management.
• Company 2 - 39% below our estimate - expands coconut based drinks as they move from niche shelves into mainstream retailers and private label aisles.
• Company 3 - 36% below our estimate - targets complex outsourced manufacturing wins in regulated end markets where new program awards shape revenue visibility.

Three companies from the same screener. Open every one of the 28 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com